Tag Archives | HCV

2018 Biopharmaceutical Performance-Large Caps: Big winners were Merck and Vertex…Update- Rally Underway

http://broughtonpublishing.com.au/new-book-about-the-anglican-church-and-community-in-melbourne-during-the-great-war/ 11/16…TSRO Alert at $35, Up 32%, Company is for Sale 11/15p After Close…Traders: Rally is intact but needs another green day to confirm. Big mid-cap 4% movers today: AGIO ARNA (up 21.6%) ARRY CRSP LOXO NBIX ICPT SRPT  XNCR We added small positions over the past week in ABBV AMRN KPTI QQQ XLV and XBI as […]

Continue Reading 0

Biotech Momentum Lost Mired in Macro-Economic News Cycle: China, FED,Trade etc.

follow site Biotech Momentum Lost Technical Breakdown: XBI Near April Bottom but XLV Looks Good Market Looking for Growth from Large Cap Earnings 10 year auction has tepid demand at Yield of 3.225%, NASDAQ at 7602 own 1.75% (Prices as of mid-day 1:30 p EDT) Biotech momentum losses were triggered by a reversal in investor psychology  because […]

Continue Reading 0

Rayno BioBeat #6: Biotech Sell-Off with Broad Market Concerns…Updates

here Update 10/5/18 Very Weak Technicals after Biotech Sell-Off NASDAQ market closed off the lows down 1.16% at 7788. Biotech ETF IBB down 1.15% just above 3 month support of 116. Biotech ETF XBI down 1.51% at 90.45 broke downtrend line and May support at 92. More losers again but a several winners: e.g. BLUE,CRSP,IONS,RHHBY. Our […]

Continue Reading 0

Biotech Weakness but why Large Caps?…Updates

Update: 10:10a Tesaro (TSRO) Soars 15% to $38, short covering or bargain hunters? News item: expansion of Zejula Combo Trial in NSCLC ========= Biotech Weakness in Large Caps Mid-Caps Have Continued Strength The overall market recovered from an early sell-off but there was pronounced biotech weakness as well as in healthcare stocks one of the […]

Continue Reading 0

Rayno Biopharma Portfolio 2018 YTD: Performance Summary

9/10 Update: Long Tesaro (TSRO) We added small positions at $32 on August 21 and more on 9/7 at $35+. =============== Rayno Biopharma Performance 2018: YTD 8/4 Large Caps Begin to Outperform FBT Is the Best All Around Life Science Play up 19% YTD We have provided herein a summary of biopharma portfolio positions for […]

Continue Reading 0

Biotechs Sell-Off Last Week: Growth Disappointing or Just Profit Taking? …Updates

Update 7/30 at close- –Large Caps Outperform-Very Weak Tape NASDAQ continues slide down 1.39% Large Cap Leaders ABBV up 0.89%, BMY up 3.53%, CELG up 2.87%,MRK up 2%,REGN up 1.06%, VRTX up 1.35%. BIIB down 2.63%. Mid-Cap Red Screen:  ACAD down 4.08%, ALNY down 7.37%, BLUE down 4.46%, IMMU down 3.45%, NBIX down 7.68% IBB […]

Continue Reading 0

Biotech Bull Market: ETFs and Life Science Mutual Funds 2018 YTD

Biotech Bull Market: Up 25.39% Over 2 Years With High Volatility  XBI Outperforms Up 12% YTD; FBT is Comparable, IBB lags. Three Funds did well in H1 2018 (7-9%). Biotech stocks peaked in July 2015 and reached a bottom on 10/31/16 gradually clawing their way back to a level about midway between the highs and lows […]

Continue Reading 0

Biotechs Soar After Big Trump Drug Price Speech- Mid-Caps Should Outperform…Updates

Update: 5/17…Mini-Rally Continues With Help From ASCO Abstracts XBI hits $93.78 above April highs, up 5.32% over 5 days, 10.5% YTD. IBB at April highs at $107.59, up 3.62% over 5 days, up 0.77% YTD Many Mid-Caps are hot: BLUE, CRSP, EXEL, FOLD, LGND, LOXO. See our list below. Gene editing stocks move up: CLLS, […]

Continue Reading 0

Biotechs Survive 2018 Bottom and Catch a Rally Today…Update 5/9

Update 5/8/18 Biotechs Rally Above Near Term Support (XBI) at SMA 20 XBI up 1.96% to $89.80. IBB up 1.35% to $103.79; twelve month quadruple bottom is near $100 level. Small and mid caps should outperform because of news and M&A potential. Large caps: Celgene (CELG) down 20.66% over 12 month lows at $82.80. Large caps: Abbvie(ABBV) […]

Continue Reading 0

Biotechs Bounce From Support Levels Despite Mixed Earnings Reports…Update 5/3- Testing 2018 Lows

5/3 Testing February bottom and 200 MA of ~$100 on IBB and ~$85 on XBI. Red screen day. 2PM EDT Dow near flat line. Need to look for major gap up. Another potential negative on the horizon: “Bold Action on Drug Pricing” by Sect’y HHS. 5/2  Biotech Stocks Are About To Test 2018 Lows: It […]

Continue Reading 0